The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
Eric S. Winer
No relevant relationships to disclose
Howard Safran
No relevant relationships to disclose
Boguslawa Karaszewska
No relevant relationships to disclose
Donald A. Richards
No relevant relationships to disclose
Lee Hartner
No relevant relationships to disclose
Frederic Forget
No relevant relationships to disclose
Rodryg Ramlau
No relevant relationships to disclose
Kirushna Kumar
Research Funding - Investigator Fees
Bhabita Mayer
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Brendan Mark Johnson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Conrad A. Messam
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yasser Mostafa Mostafa Kamel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline